Ventana Medical Systems Inc., part of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum) and University Hospital Heidelberg, Germany, to commercialize a novel immunohistochemistry (IHC) primary antibody. Designed to detect the V600E BRAF mutation protein, the new IHC diagnostic from Ventana will add to Roche's portfolio of BRAF diagnostics.
The BRAF protein plays a role in regulating cell signaling, and it has been shown to be mutated in many human cancers. The Ventana antibody is being developed both as an in vitro diagnostic and for research use only. These products are expected to be the first validated, commercially-available IHC antibodies capable of specifically detecting BRAF mutations, claims Ventana Medical in a press release.
The company also notes that cancer researchers are evaluating applications of V600E mutation testing in the diagnosis, prognosis, and prediction of patient response to therapy in major cancers including colorectal, thyroid, brain, and non-Hodgkin lymphoma.